Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism

Contemporary Clinical Trials

Volumn 32, Issue 6, 2011, Pages 829-833

  Parpia, S ^a   Julian, J A ^a   Thabane, L ^b   Lee, A Y Y ^c   Rickles, F R ^d   Levine, M N ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Cancer; Competing risks; Cumulative incidence function; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN;

ADULT; ADVANCED CANCER; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL; THERAPY EFFECT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 80053385866     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.07.005     Document Type: Article

References (18)

1. Prentice R.L., Kalbfleisch J.D., Peterson A.V., Flournoy N., Farewell V.T., Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics 1978, 34:441-444.
2. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:694-706.
3. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
4. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1948, 43:447-481.
5. Clark T.G., Bradburn M.J., Love S.B., Altman D.G. Survival analysis part I: basic concepts and first analyses. Br J Cancer 2003, 89(2):232-238.
6. Kim H.T. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007, 13:449-464.
7. Satagopan J.M., Ben-Porat L., Berwick M., Robson M., Kutler D., Auerbach A.D. A note on competing risks in survival analysis data. Br J Cancer 2004, 91:1229-1235.
8. Bland J.M., Altman D.G. Survival probabilities (the Kaplan-Meier method). BMJ 1998, 317:1472.
9. Kalbfleisch J., Prentice R. The statistical analysis of failure time data 1980, John Wiley & Sons, United States.
10. Tai B.C., Grundy R.G., Machin D. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. basic concepts and first analyses. Int J Radiat Oncol Biol Phys 2010, 76:1493-1499.
11. Williamson P.R., Kolamunnage-Dona R., Tudur Smith C. The influence of competing-risks setting on the choice of hypothesis test for treatment effect. Biostatistics 2007, 8:689-694.
12. Farley T.M., Ali M.M., Slaymaker E. Competing approaches to analysis of failure times with competing risks. Stat Med 2001, 20:3601-3610.
13. Green S., Benedetti J., Crowley J. Clinical trials in oncology 2002, Chapman & Hall/CRC, New York. Second ed.
14. Pintilie M. Competing risks: a practical perspective 2006, John Wiley & Sons Ltd, England.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 40:163-170.
16. Gray R.J. A class of K-sample tests comparing cumulative incidence of competing risks. Ann Stat 1988, 16:1141-1154.
17. Cox D.R. Regression models and life-tables. J R Stat Soc B Methodol 1972, 43:187-220.
18. Fine J.P., Gray R.J. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.